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Dear Readers, 
LABRAD continues to enjoy a pan Pakistan reach 
and also many hits on e commons(https://ecommons.
aku.edu/labrad/) by both national and international 
readers.  I shall assure all our readers that my team’s 
consistent efforts will be aimed toward increasing 
the visibility, impact, and the overall quality of 
LABRAD. I hope our readers  share a similar vision, 
and we look forward to a productive, challenging 
and successful 2019 ahead. In this issue you will find 
two new sections added: ‘Polaroid’ and ‘Best from 
the Past’. In the spirit of continuous improvement 
feedback  from you is very welcome. 
In your hands you hold LABRAD’s second issue for 
the year 2019. This issue is non-thematic with some 
interesting reads like ‘Role of Serum Galactomannan 
(GM) Assay in Diagnosing  Invasive Aspergillosis, 
‘Direct Immunofluorescence in Bullous Skin 
Disorders’, ‘PET/CT Hybrid Imaging Technology’ 




From the Editor’s Desk
Novel Molecular Technique for Identifying 
Respiratory Tract Pathogens
Ms Ghazala Jabeen and Dr Mohammad Zeeshan
Microbiology 
Today we are breathing in a gloomy global 
environment which is contaminated with 
poisonous gases, dirt and unsolicited microbes. 
Our respiratory health is at stake and contributing 
disease burden of different etiologies throughout 
the globe.
Acute respiratory tract infections with spectrum 
of etiological agents contribute significantly 
in the morbidity and mortality of population 
with different associated comorbid e.g. 
children, adult with structural lung disease and 
immunosuppressed masses. Laboratory diagnostic 
curbs for respiratory infections further complicate 
the consequence. This sometime compel physician 
to use antibiotics when it could possibly be 
avoided and hence promotes emerging antibiotic 
resistance with heedless financial impact. 
The causative agents of community associated 
upper respiratory infections are typically self-
limiting viral etiology. The spectrum of pathogens 
involving lower respiratory tree include viral, 
bacterial and fungal agents associate with 
host’s risk factors.  The advents of emerging 
immunocompromise population in this era 
necessitate the need of diagnostic accuracy for 
respiratory pathogens to get better therapeutic 
outcomes. 
 
In a routine clinical microbiology laboratory 
respiratory specimen culture and serological tests 
are the main stay of diagnosis. These methods are 
affective but limits it use because of  specimen’s 
quality, limited yield of causative agents, inability 
to cultivate certain pathogens e.g. viruses, cell 
membrane deficit bacteria and consumption of 
diverse types of culture media for cultivation. 
Non culture base diagnostic armamentarium e.g. 
antigen and antibody based diagnostic methods has 
been in use for long time for respiratory infectious 
diseases, however, there diagnostic accuracies 
are not always helpful. These diagnostic kits are 
sometime strain specific, with the use of specific 
diagnostic epitopes or antigens in kit and cross 
reactivity due to antigenic sharing. Results might 
also be deviate with the host’s immune response. 
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Microbiology department has introduced FDA 
approved multiplex PCR film array RP2 Panel 
to detect the pathogens of upper respiratory tract 
infections .The panel can detect 18 viruses and four 
bacteria within turnaround time of one hour and 
overall sensitivity and specificity of 95 percent and 
99 percent respectively. This Panel system integrates 
three simple steps 
Molecular technique by amplifying nucleic 
acid of causative agents of respiratory tract 
infection in a single specimen has improved 
the diagnosis. The technology using multiplex 
PCR coupled with fluidic or fixed microarrays 
and provides a sensitive and comprehensive 
approach for the diagnosis of respiratory tract 
infections. 
STEP 1: Sample preparation STEP 2: Amplification STEP 3: Detection & analysis
1 - Insert pouch to loading station
Fig. 1 Sample preparation and test performance steps
Table 1 Organisms detected by Bio Fire RP2 panel 
Viruses Bacteria
3 - Inject sample
2 - Inject hydration solution
























In conclusion, this molecular testing methods will 
significantly expanded our ability to diagnose 
respiratory infections because of its rapidity, 
sensitivity, and potential for the simultaneous 
detection of 22 respiratory pathogens. Use of 
rapid and accurate diagnostic test increase the 
ability of clinical decision making and results in 
less antibiotics use help to promote the use of cost 
effective treatment strategies.
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Role of Serum Galactomannan (GM) Assay in 
Diagnosing Invasive Aspergillosis (IA)
The estimated disease prevalence of invasive 
aspergillosis (IA) ranges between 2.9 to 10 percent 
in Pakistani population with different underlying 
comorbids.
Definite diagnosis of IA needs multidisciplinary 
approach which includes radiological imaging, 
histopathology tissue biopsy and microbiological 
culture. This is a perplexing task for a physician to get 
all these tests timely and simultaneously especially in 
low resource settings where the availability of all these 
modalities is difficult as it require invasive procedures 
to get appropriate specimen. These diagnostic 
challenges in immunocompromised cadre lead to high 
morbidity and mortality.
The advent of Aspergillus antigen assay –
Galactomannan (GM) contributes significantly in 
the early diagnosis of IA. It is a soluble aspergillus 
specific antigen that is released during the growth 
phase of invasive aspergillosis. The assay is a 
one-stage immunoen-zymatic sandwich microplate 
serologic method. 
European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID), the European 
Confederation of Medical Mycology (ECMM), the 
European Respiratory Society (ERS) joint clinical 
guidelines and infectious disease society of America 
(IDSA) has endorsed GM in the diagnosis of IA.
Mr Syed Faheem Naqvi and Dr Mohammad Zeeshan
Microbiology 
Table 1 Galactomannan assay Interpreting Values
Physicians must correlate assay results in view with 
underlying comorbid, clinical condition, microbiologic 
and radiological evidence. Serial assays can be helpful 
in case of high clinical suspicious. 
One of the important limitations of this assay is the 
false positive result due to various factors which 
must keep in consideration when interpreting GM 
results. Wrong interpretation can lead to injudicious 
start of antifungal therapy. Numbers of factors which 
are involved in the false positive GM assay are as 
follows:  
1. Cross-reactivity with therapeutic agent like:
  a. Plasmalyte. 
  b. Antimicrobial agents:  amoxicillin, 








Single ≥ 0.7 or two 
consecutive 
samples of > 0.5
Note: >1.0 is considered 







Fig. 1 Principle and procedure of Galactomannan Assay
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Factor VIII Inhibitor – A Diagnostic Approach
Dr Abdul Muqtadir Abbasi 
Hematology & Transfusion Medicine
Introduction
Acquired inhibitors of coagulation are antibodies 
that either inhibit the activity or increase 
the clearance of a clotting factor. A common 
clinical manifestation in affected patients is 
a hemorrhagic diathesis. The most common 
autoantibodies that affect clotting factor activity 
and lead to a bleeding disorder are directed 
against the activity of factor VIII, also called 
acquired hemophilia A. Most of factor VIII 
autoantibodies, have been IgG antibodies that do 
not bind complement.
The reasons for the production of factor VIII 
autoantibodies may involve the presence of certain 
gene polymorphisms (eg, HLA, CTLA4) and/or 
autoreactive CD4+ T lymphocytes.
An individual patient, either non-hemophilic or 
hemophilic, can produce antibodies of different 
IgG subclasses directed against different epitopes 
on the factor VIII molecule. However production 
of multiple antibodies is much more common in 
patients with hemophilia. Most of these antibodies 
bind to the C2 or, less often, the A2 domain on 
factor VIII. Loss of the C2 domain, which binds to 
the pro-coagulant phospholipid phosphatidylserine 
on activated platelets and endothelial cells and 
to von Willebrand factor, leads to reduced pro-
coagulant activity.
The most common associated conditions were 
malignancy, post-partum status, and autoimmune 
disorders.
Clinical Features
Symptomatic patients often present with 
large hematomas, extensive ecchymoses or 
severe mucosal bleeding, including epistaxis, 
gastrointestinal bleeding, and gross hematuria. 
Spontaneous hemarthroses, which are common 
in hereditary factor VIII deficiency, are unusual 
in those with acquired disease. Bleeding is often 
severe, constituting a medical emergency.
Diagnosis
The sudden presence of large hematomas or 
extensive ecchymoses in an elderly individual 
without significant trauma or known bleeding 
disorder should always raise the clinical 
suspicion of an acquired factor VIII inhibitor. 
Following tests are required to accurately reach 
the diagnosis.
   chrysogenum, Alternaria specie) and 
   bacterial species (e.g. In E.coli and 
   Enterococcus faecalis bacteremia 
There are causes of false negative results e.g. 
prior or concomitant administration of antifungal 
drugs, dependency on site of infection, growth and 
specie type (low sensitivity for A.fumigatus) and 
inappropriate testing, sampling and storage. 
In conclusion, Galactomannan assay though a useful 
diagnostic marker, but the result interpretation must 
be performed very carefully and must correlate with 
clinical conditions and rule out the causative factors 
associated with false positive and false negative 
result.
   amoxicillin-clavulanate and  Piperacillin- 
   tazobactam.
2. Cross reactivity with foods: 
  a. High GM content in pasta, rice, peas, 
   carrots, mushroom and spinach. Diet 
   contain high contents of these food can 
   raise GM level.
3. Cross reactivity due to immunologic reaction: 
  a. In liver transplant recipients: Patients 
   with autoimmune liver disease were 
   more likely to have false-positive 
   tests than other liver transplant 
   patients. 
4. Cross reactivity with pathogens: 
  a. Non aspergillus fungal Species (e.g.  
   Penicillium marneffei, Penicillium 
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Coagulation Tests 
Factor VIII inhibitors are characterized by a 
prolonged activated partial thromboplastin time 
(aPTT) and a normal prothrombin time (PT). The 
differential diagnosis in this scenario includes 
deficiencies of factors XI, IX or VIII, von Willebrand 
disease, inhibitors of these factors, and the use of 
heparin (Table 1). A prolonged aPTT is also seen in 
the antiphospholipid antibody syndrome, but these 
patients typically present with thrombosis rather than 
bleeding episodes.
Table 1 – Causes of isolated prolonged aPTT
PT APTT
Normal Prolonged Inherited
Deficiency of factor VIII, IX, or XI
Deficiency of factor XII, prekallikrein, or HMW kininogen (not associated with a bleeding diathesis)
von Willebrand disease (variable)
Acquired
Heparin, dabigatran, argatroban, direct factor Xa inhibitors (variable)
Acquired inhibitor of factor VIII, IX, XI, or XII
Acquired von Willebrand syndrome
Lupus anticoagulant (more likely to be associated with thrombosis than bleeding) 
A reasonable first step is to exclude the use of 
heparin as a cause of the patient’s bleeding and/or 
prolongation of the aPTT. Also review the patient’s 
medications.
The simplest approach is to redraw a blood sample 
using an uncontaminated peripheral vein. If the 
repeat aPTT is normal, the original sample was 
probably contaminated with heparin. Then perform 
a thrombin time and a reptilase time. Heparin is 
present if the thrombin time is prolonged and the 
reptilase time is normal.
Inhibitor screen (mixing test) — The initial 
diagnostic test for a factor VIII inhibitor is the 
mixing test or inhibitor screen. In this assay, varying 
amounts of patient plasma and pooled normal plasma 
are mixed and the aPTT measured. After mixing, 
measurement of the aPTT should be performed not 
only immediately but also after incubation at 37ºC 
for one to two hours. The second measurement 
is necessary to detect factor VIII inhibitors with 
slow reaction kinetics. Correction of the prolonged 
aPTT suggests a factor deficiency or VWD, while 
persistent prolongation of the aPTT indicates 
the presence of an inhibitor. The mixing test will 
establish whether an inhibitor is present but will not 
identify the inhibitor’s specificity.
The next step is adding a source of phospholipid to 
the mixed plasma. Correction of the aPTT suggests 
the presence of antiphospholipid antibodies. If 
the aPTT does not correct, the Bethesda assay is 
performed. The Bethesda assay both establishes 
the diagnosis of a factor VIII inhibitor and 
quantifies the antibody titer. By standardizing the 
strength of factor VIII inhibitors, this assay also 
permits comparison between different treatment 
regimens.
Bethesda assay — In the Bethesda assay, serial 
dilutions of patient plasma are incubated with pooled 
normal plasma at 37ºC for two hours; factor VIII 
activity is then measured using a clotting assay as 
one would in a patient with hereditary factor VIII 
deficiency. The reciprocal dilution of patient plasma 
that results in 50 percent factor VIII activity is 
defined as one Bethesda unit (BU). The stronger the 
inhibitor, the greater the dilution required to allow 
for factor VIII activity.
8
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PET/CT Hybrid Imaging Technology at Aga 
Khan University Hospital
Professor Maseeh uz Zaman 
Radiology 
PET/CT is the cutting edge 
hybrid imaging (fused) 
technology of this century 
and has become a standard of 
care in many cancers. AKU 
in pursuance of its vision 
to deliver quality care to its 
valued patients has stepped 
into PET/CT arena with 
an unprecedented donors’ 
support. For imaging tumour 
within body, a radiolabelled 
glucose (FDG) produce by 
a cyclotron is required and 
a reliable and sustainable 
supply is mandatory to run 
PET/CT scanner. Keeping in 
view of unavoidable and not 
uncommon frequent interrupted FDG supply to other 
user in Karachi, AKU wisely decided to acquire a 
cyclotron as well to ensure a reliable and sustainable 
supply of FDG.
AKU selected the state of the art PET/CT scanner 
(Celesteion®) which was launched in 2014 and 
the first in this part of world. We selected this 
machine for its best imaging and patient’s friendly 
specifications as compared to others. For FDG 
supply, AKU selected a cyclotron of USA make 
(ABT, Dose on Demand®) having the smallest foot 
print and need one-two operators to run this fully 
automated highly sensitive but complicated unit. 
This ABT cyclotron in each run (90-120 minutes/
run) produces FDG for three-four patients. However, 
compared to conventional large foot-print cyclotron, 
this Dose-On-Demand cyclotron cannot be used to 
supply FDG to users outside AKU.
We start our work at 7.0 am in morning by starting 
the ABT cyclotron to ensure to have first production 
of FDG around 9.0 am and patients are scheduled 
from 8.30 am onward. Patients are advised to come 
with four hours fasting to ensure their fasting glucose 
level < 200 mg/dl to avoid rescheduling.
After FDG injection, patients are advised to lie 
comfortably and not vocalize to ensure good uptake 
of FDG by tumour. After about 50 minute, patient is 
move to PET/CT scanner which takes 15 minute to 
acquire images from head to mid-thigh. Once images 
are acquired, these are reviewed for adequacy and 
patient is released with pertinent post-procedural 
instructions.
We do PET/CT on daily basis (05working day/
week) and on average 8-12 patients/day. However, 
sometime number goes below that figure due to 
inadequate preparation (most common reason is 
fasting blood glucose >200 mg/dl).  PET/CT suite is 
also being utilized very efficiently for CT Treatment 
Planning (CTP) of radiotherapy patients. Around 4-5 
patients of CTP are done on alternate days (two days) 
and two-three on patients PET/CT days as well (03 
days). AKUH is the only facility in Pakistan which is 
using FDG PET/CT imaging for treatment planning 
of tumour (Image Guided Radiation Therapy, FDG 
PET/CT based IGRT).  
So far we have done 4353 patients from 18th 
December 2015 till 30th April 2019. 
Graph is attached below.
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Von Willibrand disease (VWD) is the most common 
inherited mucocutaneous bleeding disorder resulting 
from deficiency or defective plasma von willibrand 
factor. Von willibrand factor plays important role 
in primary and secondry hemostasis. It binds to 
collagen in exposed endothelium that enables it to 
adhere to platelets at the site of blood vessel demage 
through binding with Gp1b. It also carries factor VIII 
in plasma, protecting it from premature proteolysis 
and delivers it to site of blood vessel damage.
Types of Von Willibrand Disease
There are three major types of VWD 
 l Type 1 is due to a quantitative reduction in 
  Von Willibrand factor (VWF) [both 
  concentration and activity are decreased].
 l Type 2 is due to dysfunctional VWF.
 l Type 3 is due to absent or severely reduced 
  VWF.
Laboratory Testing
Baseline hemostasis assessment: VWD generally 
will have a normal blood counts and a normal 
platelet count, with the exception of those with 
type 2B VWD, most of whom will have mild 
thrombocytopenia and may have a normal or 
prolonged activated partial thromboplastin time 
Diagnostic Tests for Von Willebrand Disease
Dr Qadeer Ahmed
Hematology & Transfusion Medicine
(aPTT), depending on the degree of reduction of 
the factor VIII level. The prothrombin time (PT) is 
normal in VWD.
VWD screening tests: For initial testing for VWD, 
there are three screening tests that assess the quantity 
and function of von Willebrand factor (VWF).
VWF antigen (VWF:Ag) – Quantitative 
measurement of VWF protein level: Plasma 
VWF:Ag measures the quantity of VWF protein 
in the plasma and most testing is now done using 
an enzyme-linked immunosorbent assay (ELISA)-
based method on microtiter plates or by other 
automated methods using latex beads coated with 
antibodies to VWF and patient plasma as the source 
of VWF.  
A VWF:Ag level <30 percent (<30 international 
units/dL) is consistent with VWD. Levels between 
30-50 percent indicate “low VWF.” Levels >50 
percent are considered normal.
VWF activity (VWF:Act) – Functional assays of 
VWF binding to platelets or collagen.
VWF:RCo (ristocetin cofactor):  VWF:RCo is an 
assay that measures the ability of VWF to bind to 
platelet membrane receptor GPIb. In the VWF:RCo 
assay, ristocetin is added to patient plasma along 
PET/CT images are reviewed and reported very 
diligently by a team of a senior Nuclear Medicine 
and Radiologist. Presently we have two Nuclear 
Medicine Consultants and six Radiologists team who 
are involved in reporting PET/CT examinations.
To run the PET/CT and cyclotron facilities 
parallel daily, we have an efficient team of four 
technologists. This is to mention that PET/CT 
and Cyclotron team of AKU is the smallest one as 
compared to others PET/CT facilities and this is due 
to a fully automated cyclotron and state of the art 
PET/CT scanner.
Recently we have also embarked upon into tele-
reporting of PET/CT studies being sent to our 
PET/CT section from other countries. Due to 
an excellent coordinated efforts of our IT team, 
technologists and reporting physicians, we have 
been maintaining a reporting turn-around time of 
100 percent (within 24 hour).
0 200 400 600 800
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with washed or formalin-fixed platelets, and the 
amount of functional VWF in the plasma that causes 
platelet agglutination is quantified using platelet 
aggregometry or a manual (tilt tube) method.
VWF:Ab – VWF:Ab is an automated assay that 
measures binding of a specific monoclonal antibody 
to the GPIb binding site on VWF.
Collagen binding – VWF binding to collagen allows 
VWF to be localized to the subendothelial matrix, 
bringing bound platelets to the site of vascular 
injury. Assays for collagen binding are performed 
using ELISA plates coated with collagen (typically 
collagen types I and III).
Factor VIII activity: Decreased factor VIII activity 
may indicate reduced or dysfunctional VWF because 
VWF acts as a carrier for factor VIII that protects 
it from proteolysis, increasing its plasma half-life. 
Significant reduction in VWF can decrease factor 
VIII sufficiently to prolong the aPTT. 
Other Screening Tests
Platelet function analyzer (PFA) assay: 
A membrane that is coated with collagen , ADP, or 
epinephrine and has a central aperture. The time to 
closure of the aperture as the platelet plug forms is 
measured. The closure time is dependent upon both 
VWF and intrinsic platelet function.
Bleeding Time 
  
Measures interaction of platelet with blood vessel 
wall. BT is time consuming and highly operator 
dependent procedure.  BT may be abnormal in 
individuals with VWD , but a normal BT does not 
eliminate the possibility of VWD. 
Ratio of VWF Activity to VWF Antigen 
 
Ratio  of VWF:Act to VWF:Ag as a means 
of helping to identify patients with type two 
VWD (dysfunctional VWF; qualitative defect). 
Typically, the ratio of the ristocetin cofactor activity 
(VWF:RCo) or the collagen binding activity 
(VWF:CB) to VWF:Ag is used. A ratio >0.7 is 
generally considered consistent with type 1 VWD, 
with probable lower limits in the range of 0.5 to 0.7.  
A ratio of <0.5 to 0.7 is considered consistent with 
type two VWD.
VWF Multimer Analysis 
The multimer proteins are separated by agarose 
gel electrophoresis, and multimers of different 
sizes are detected using anti-VWF reagents after 
transfer to a membrane (eg, Western blotting with 
chemiluminescence detection). Multimer distribution 
can be quantified with densitometry of agarose gel 
bands.
Ristocetin-Induced Platelet Aggregation (RIPA)
RIPA measures the affinity with which VWF binds to 
the platelet receptor GPIb. The presence or absence 
of platelet aggregation is noted at each concentration 
of ristocetin. Platelet rich plasma (PRP) from 
patients with normal VWF does not aggregate at 
concentrations of ristocetin that are lower than 
approximately 0.6 to 0.8 mg/mL, but PRP from 
patients with type 2B VWD will usually aggregate at 
concentrations of ristocetin of 0.4 to 0.5 mg/mL.
Specialized Tests for VWD
VWF propeptide (VWF:PP) — The VWF:PP 
is a protein sequence that is part of VWF when 
it is initially synthesized; it is cleaved during the 
release of VWF into the circulation, and it circulates 
independently with its own half-life. As such, it is 
a marker for the amount of newly synthesized and 
released VWF. When VWF has a short half-life (as 
in rapid clearance of VWF due to any cause), the 
ratio of VWF:PP to VWF:Ag is elevated (ratio >3). 
VWF:PP to VWF:Ag ratio is helpful in the diagnosis 
of acquired von Willebrand syndrome.
VWF binding to factor VIII (VWF:FVIIIB) — 
VWF mutations in the binding site for factor VIII 
cause decreased binding of VWF to factor VIII 
leading to low levels of factor VIII and the diagnosis 
of VWD type 2N. The binding assay is usually 
performed in an ELISA format, using the patient’s 
plasma VWF to coat the wells and recombinant 
factor VIII as the added binding protein. The ability 
of the patient’s plasma VWF to bind factor VIII is 
compared with that of a normal plasma pool. 
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Iron deficiency anemia arises when the balance of 
iron intake, iron stores, and the body’s loss of iron 
is disturbed, leading to insufficient production of 
erythrocytes. The WHO defines anaemia in adults 
as a haemoglobin less than 13.0 mg/L in males and 
less than 12.0 mg/L in females. In the developed 
world, this disease is easily identified and treated, 
but frequently overlooked by physicians. In contrast, 
it is a health problem that affects major portions of 
the population in underdeveloped countries. In 2010, 
global anemia prevalence was 32.9 percent (i.e., 
more than 2.2 billion people were affected); iron 
deficiency was the most common cause.
Schematic representation of the pathways involved 
in iron (Fe) homeostasis. The amount of iron passing 
from mucosal cells into the body is determined by 
Iron Deficiency Anemia
Dr Seher Rasheed
Haematology & Transfusion Medicine





l Adolescence in girls
l Pregnancy
l Regular blood donation
Blood loss
	 l Digestive tract: colonic carcinoma, gastric  
  carcinoma, inflammatory bowel
	 l Diseases, ulcers, angiodysplasia, parasites
	 l Gynecological loss
	 l Surgery
	 l Hematuria, epistaxis, hemoptysis
	 l Hemodialysis
	 l Non-steroidal anti-inflammatory drugs,  
  aspirin
Malabsorption
	 l Coeliac disease
	 l Gastrectomy
	 l Helicobacter pylori
	 l Gut resection, atrophic gastritis, bypass 
  gastric surgery, bacterial overgrowth
	 l Interaction with food elements: tea, coffee, 
  calcium, flavonoids, oxalates, phytates
Iron deficiency anemia associated with 
anemia of chronic disease
	 l Chronic heart failure
	 l Cancers
	 l Chronic kidney disease
	 l Rheumatoid arthritis
	 l Obesity
	 l Inflammatory bowel diseases
Genetic disorders
	 l Iron-refractory iron deficiency 
  anemia
	 l Others (divalent metal 
  transporter 1 deficiency 
  anemia, Fanconi anemia, 
  pyruvate kinase deficiency, etc.)
Physiological Conditions and Pathological Disorders Associated With Iron Deficiency Anemia
Clinical Features
Iron deficiency anemia signs and symptoms may 
include:
	  Extreme fatigue
	  Weakness
	  Pale skin
	  Chest pain, fast heartbeat or shortness of 
  breath
	  Headache, dizziness or lightheadedness
	  Cold hands and feet
	  Inflammation or soreness of your tongue 
  (Glossitis)
	  Brittle nails, spoon shaped nails (Koilonychia)
	  Unusual cravings for non-nutritive 
  substances, such as ice, dirt or starch (Pica)
	  Poor appetite, especially in infants and 
  children with iron deficiency anemia
12
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Complications
Mild iron deficiency anemia usually doesn’t cause 
complications. However, left untreated, iron defi-
ciency anemia can become severe and lead to health 
problems, including the following:
Heart problems: Iron deficiency anemia may lead to 
a rapid or irregular heartbeat. Your heart must pump 
more blood to compensate for the lack of oxygen 
carried in your blood when you’re anemic. This can 
lead to an enlarged heart or heart failure.
Problems during pregnancy: In pregnant women, 
severe iron deficiency anemia has been linked to 
premature births and low birth weight babies. But 
the condition is preventable in pregnant women who 
receive iron supplements as part of their prenatal care.
Growth problems: In infants and children, severe 
iron deficiency can lead to anemia as well as 
delayed growth and development. Additionally, iron 
deficiency anemia is associated with an increased 
susceptibility to infections
Laboratory Diagnosis of Iron Deficiency Anemia
Typically, the evaluation of the cause of anemia 
includes a complete blood cell count, peripheral 
smear, reticulocyte count, and serum iron indices. 
The severity of anemia is based on the patient’s 
hemoglobin/hematocrit level.
Red Cell Indices and Blood Film
Even before anemia occurs, the red cell indices fall 
and they fall progressively as the anaemia becomes 
more severe. The mean corpuscular volume is the 
measure of the average red blood cell volume and mean 
corpuscular hemoglobin concentration is the measure 
of the concentration of hemoglobin in a given volume 
of packed red blood cells. The normal reference ranges 
for mean corpuscular volume is 80–100 fL and mean 
corpuscular hemoglobin concentration is 32.0–36.0 g/l. 
The patient’s cells are said to be microcytic and 
hypochromic, respectively, when these values are less 
than the normal reference range.
Microcytic hypochromic anemia of iron deficiency 
(peripheral blood smear)
Serum Iron and Total Iron‐Binding Capacity 
The serum iron falls and total iron‐binding capacity 
(TIBC) rises so that the TIBC is less than 20 percent 
saturated. This contrasts both with the anaemia of 
chronic disorders, when the serum iron and the TIBC 
are both reduced, and with other hypochromic ane-
mia where the serum iron is normal or even raised.
Serum Ferritin 
A small fraction of body ferritin circulates in the 
serum, the concentration being related to tissue, 
particularly reticuloendothelial, iron stores. The 
normal range in men is higher than in women. In iron 
deficiency anaemia the serum ferritin is very low 
while a raised serum ferritin indicates iron overload 
or excess release of ferritin from damaged tissues or 
an acute phase response (e.g. in inflammation). The 
serum ferritin is normal or raised in the anaemia of 
chronic disorders.
Bone Marrow Iron
Bone marrow examination is not essential to assess 
iron stores except in complicated cases. In iron 
deficiency anaemia there is a complete absence of 
iron from stores (macrophages) and from developing 
erythroblasts. The erythroblasts are small and have a 
ragged cytoplasm.
The blood film shows hypochromic, microcytic 
cells with occasional target cells and pencil‐shaped 
poikilocytes. The reticulocyte count is low in relation 
to the degree of anemia. The platelet count is often 
moderately raised in iron deficiency.
Laboratory Diagnosis of Iron Deficiency Anemia 
MCV/MCH Reduced in relation to 









MCH, mean corpuscular hemoglobin; 
MCV, mean corpuscular volume; TIBC, 
total iron‐binding capacity
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Bone marrow iron assessed by Perls’ stain. (a) 
Normal iron stores indicated by blue staining in 
the macrophages. Inset: normal siderotic granule in 
erythroblast. (b) Absence of blue staining (absence 
of haemosiderin) in iron deficiency. Inset: absence of 
siderotic granules in erythroblasts.
Soluble Transferrin Receptor
Soluble transferrin receptors are proteins found 
in blood that can be elevated with iron deficiency. 
This test measures the amount of soluble transferrin 
receptors to help detect and evaluate iron deficiency 
and distinguish it from anemia caused by chronic 
illness or inflammation.
 
Transferrin is the main protein in the blood that binds 
to iron and carries it to tissues and cells throughout 
the body. About 80 percent of iron is transported to 
the bone marrow, where it is incorporated into the 
hemoglobin in red blood cells (RBCs), and the rest 
is stored in other cells and tissues as ferritin and 
hemosiderin.
Usually, a ferritin test is used to 
evaluate the amount of iron reserve 
in the body and to help diagnose iron 
deficiency anemia. However, the 
ferritin level can be elevated when 
an individual has inflammation or a 
chronic disease, such as autoimmune 
disorders or some cancers. In 
these conditions, the ferritin test 
is not useful and a test for soluble 
transferrin receptors may be ordered.
Reticulocyte Haemoglobin Equivalent
Measuring the haemoglobin content of reticulocytes, 
also known as RET-He or reticulocyte haemoglobin 
equivalent, is a way of diagnosing and monitoring 
iron deficiency anemia. Measuring the haemoglobin 
content of the reticulocytes as a direct assessment 
of the iron actually used for the biosynthesis of 
haemoglobin can indicate whether there is enough 
iron available for erythropoiesis. 
The clinical utility of the Ret-He parameter has been 
proven and it is now an established parameter in 
advanced haematological analysis. Considered the 
most sensitive indicator of current iron availability 
for erythropoiesis
Differential Diagnosis
IDA is classically described as a microcytic anemia. 
The differential diagnosis for microcytic anemia 
includes iron deficiency, thalassemia, sideroblastic 
anemias, some types of anemia of chronic disease, 
and lead poisoning (rare in adults).
(a) (b)
cystic fibrosis transmembrane conductance regulator 
(CFTR) gene that encodes the CFTR protein, an 
ion channel protein which transports chloride ions 
across the membranes of cells that line airways, 
glands and digestive tract. Outcome of a CF patient 
depends on timely and accurate diagnosis. According 
to the Cystic Fibrosis Foundation consensus report, 
the criteria for the diagnosis of CF includes CFTR 
protein abnormality with biological evidence of 
Cystic fibrosis (CF) is a common potentially life 
limiting genetic disease, affecting 0.737 - 1/10,000 
live births. It is an autosomal recessive disorder 
causing multisystem disease with viscous secretions 
in the lungs, bronchi, biliary tract, intestines 
and pancreas. In the lungs, the mucus clogs the 
airway and traps germs like bacteria, leading to 
infections, inflammation, respiratory failure and 
other complications. It is caused by mutations in the 
Sweat Testing for Diagnosis of Cystic Fibrosis 
Dr Tayyaba Hassan and Ms Humera Asif
Chemical Pathology
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channel dysfunction (i.e., abnormal sweat chloride 
concentration) or identification of a CF disease-
causing mutation in CFTR gene).
Diagnosing cystic fibrosis is a multistep process, and 
should include a newborn screening, followed by 
confirmatory genetic testing. To evaluate if an infant 
has cystic fibrosis, sweat test can also be conducted 
if the infant is atleast two weeks old as the children 
with cystic fibrosis clearly show elevated electrolyte 
concentrations in their sweat compared with the 
children unaffected by the disease. At Aga Khan 
clinical laboratory, a screening test for CF sweat 
conductivity test is available. 
Sweat Test Procedure
Prior to the sweat testing, detailed history of the 
patient is taken on a structured questionnaire and 
hydration status of the patient is assessed. For sweat 
collection, an area of skin on the arm free of cuts, 
rashes and inflammation is selected. Pilocarpine 
gel, a medicine that makes the sweat glands 
produce sweat, is applied on the flexor surface of 
the forearm after washing with water and patted 
dry. The sweat analysis system (Nanoduct, Wescor 
Inc., Logan, Utah, Biomedical products Division ) 
is used for sweat testing and results interpreted by 
continuous –flow analysis on the analyzer display. 
Results considered abnormal if values >50mmol/L 
(equivalent NACL).
Test should be conducted at room temperature (22-
25 °C) with a relative humidity of approximately 
60  Percent. The electrical conductivity of sweat is 
a function of total ionized particles in the sweat i.e. 
sodium potassium, small amount of ammonium and 
chloride. In cystic fibrosis as the CFTR chloride 
channel is defective so chloride cannot be absorbed 
properly into sweat duct cells, resulting in high 
concentration of chloride in sweat. 
Limitations
Sweat chloride conductivity test can give false 
positive results and is cumbersome to perform. And 
since the chloride concentration in sweat is directly 
related to sweat production rate so chances of false 
negative results increases with less sweat production. 
According to the data collected, failure rate of sweat 
production is high in our population (20-40 percent, 
while <5 percent is recommendation of regulatory 
bodies). So it is advisable that patients coming for 
sweat testing are well hydrated.
feature of B-cell neoplasia is light chain restriction 
or monophasic staining with kappa and lambda. 
In normal B-cell, surface staining for light chains 
is heterogeneous; that is both kappa and lambda 
expressing B-cells are identified. The normal kappa 
to lambda ratio is approximately 2:1. In cases where 
predominant B-cell population is malignant, light 
chain restriction may be easily demonstrated with 
flow cytometry. 
Frequently, monoclonal B-cells are admixed with 
polyclonal population. In such cases, differential 
expression of normal B-cell antigens in benign and 
malignant cells is useful. By examining B-cells for 
populations with abnormal levels of CD19, CD20, 
or CD22 expression, one can isolate an abnormal 
B-cell lymphoproliferative disorders are clonal 
expansion of the various stages of B-lymphocytes 
in bone marrow, blood or other tissues. Mature 
B-cell neoplasms comprise over 90 percent of 
lymphoid neoplasms worldwide. The World Health 
Organization (WHO) classification of lymphoid 
neoplasms suggests that distinct clinical entities can 
be defined based on morphology, immunophenotype, 
genetic abnormalities and clinical features. Flow 
cytometric analysis not only assists in diagnosis 
and classification but also provides prognostic 
information for appropriate treatment of patients 
with chronic lymphoproliferative disorders. 
Amongst various abnormalities that are found in the 
evaluation for B-cell malignancies, the most useful 
Flow Cytometric Identification of Abnormal 
B-Cells
Dr Muhammad Shariq Shaikh and Dr Arsalan Ahmed
Haematology & Histopathology
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B-Cell population and demonstrate monoclonality. 
For instance, CD20 in chronic lymphocytic leukemia 
is dimly expressed whereas CD20, CD22 and CD11c 
are bright positive in Hairy Cell Leukemia. Absence 
of normal antigens and aberrant expression of other 
lineage markers (such as T-cells or myeloid antigens) 
are also useful features of abnormal B-cells. Absence 
of normal B-cell antigens provide some insight into 
prognosis as this features is frequently observed in 
High grade B-cell lymphomas.
Specimen site should also be considered while 
dealing with B-cell malignancies. The presence of 
significant number of CD10+ (Pre B-cells) is normal 
in bone marrow however their presence in peripheral 
blood is highly atypical. Expression of CD5, CD10 
and CD23 is typically low in benign lymph nodes but 
CD10 positive cells can readily be present in benign 
lymph nodes with florid hyperplasia. 
Co-expression of certain markers can readily 
be demonstrated by designing appropriate 
antibody panels that can help establishing the 
monoclonality. Multiparametric analysis of CD5 
in Chronic Lymphocytic Leukemia/Mantle Cell 
Lymphoma and CD10 in follicular lymphoma 
are prime examples which are routinely used for 
sub-classification of B-cell lymphoproliferative 
disorders.
Lastly, light scatter characteristics also provide 
important information about cells in question. 
Abnormally high forward light scatter is observed 
in large cell lymphoma and high side scatter is seen 
in hairy cell leukemia. Therefore, proper gating 
strategies are of utmost importance to avoid missing 
a malignant B-cell population.
The vesiculobullous disorders of skin are divergent 
group of disorders manifested as fluid filled blisters 
either within or below the epidermis & mucosal 
surfaces. The underlying mechanism of vesicle 
formation, level of split and dermal inflammatory 
infiltrate varies in these diseases despite a clinical 
overlapping picture. An accurate diagnosis is 
mandatory as some of them may be life-threatening 
and therefore correct characterization is of utmost 
importance. The light microscopic examination 
alone may be inadequate in many scenarios either 
due to early stage, eroded epidermis and epithelial 
regeneration.  Direct immunofluorescence (DIF) is 
extremely valuable in these cases to reach a definite 
diagnosis.
DIF is technique in which deposits of immune 
reactants can be seen in tissue by using antigen-
antibody reaction. The antigen is detected in fresh 
skin tissue by using fluorescein isothynate (FITC)-
labeled antibody. The sections are then examined 
under epifluroscence microscopy. The fresh vesicle 
is biopsied taking two third of the vesicle and one 
third of intact peri-lesional skin. If a sample is 
being obtained in the same laboratory then it can be 
immediately placed in embedding medium Tissue-
Direct Immunofluorescence in Bullous Skin 
Disorders
Dr Saira Fatima 
Histopathology 
Tek O.C.T compound. If specimen needs to be 
transported to the testing lab, then it is preferable 
to place the sample in Michel transport medium, 
which is reported to preserve the immunoreactivity 
for longer time.  Zeus solution can be an alternate to 
Michel medium in case of non-availability. Another 
method to send the specimen may be to place the 
specimen on saline-soaked gauze, then in a plastic 
bag which in turn will be put in a jar containing 
ice and delivered to the lab within two hours of the 
biopsy.
DIF is not only an adjunct tool in bullous disorders 
but also help in the diagnosis of connective tissue 
diseases & vacuities. However, guidelines for 
DIF sampling need to be followed to avoid a false 
negative report. The following are the general facts.
 • Blistering disorders –  peri-lesional skin
   –  Peri-lesional skin =  
    normal skin 
    immediately adjacent 
    to a lesion
   – Immune deposits are  
    degraded in inflamed or 
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Disease Location of Immune deposits Predominant
Immunoreactant
Sensitivity
    blistered skin which 
    can result in false 
    negative DIF
   – avoid an ulcer or an 
    area where the 
    epidermis is disrupted
   – Avoid active lesions
 • Connective tissue diseases – lesional skin
   – For SLE lupus band 
    test x 2 biopsies of 
    lesional and non-sun 
    exposed normal skin 
    (buttock or inner thigh)
   – Avoid old lesions and 
    facial lesions
 • Vasculitis  –  lesional skin
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terms intratubular germ cell neoplasia, unclassified 
type (IGCNU), carcinoma in situ (CIS) and testicular 
intraepithelial neoplasia (TIN)   
   
B-Teratomas classified as                                                                        
1. Prepubertal.                                                                                                                                     
2. Postpubertal.       
   
C-  Spermatocytic Tumor: Previously known as 
spermatocytic seminoma is not recommended term 
and is not a subtype of classical seminoma.
D-Classification of Sex-cord Stromal tumors                                 
1.Pure Sertoli cell tumours (SCT)                                                                     
2.Specific SCT variants                                                                                                                                         
 3.Pure Leydig cell tumours                                                                     
4.Adult and juvenile type granulosa cell tumors                          
5.Tumours in the fibroma-thecoma group                                          
6.Mixed and unclassified SCST’s
Formerly there were several SCT variants including        
SCT not otherwise specified (NOS),                                                        
Sclerosing SCT,                                                                                                                                             
Lipid-rich SCT and                                                                                                                                              
Large cell calcifying SCT.
Sclerosing SCT has been collapsed into the SCT 
NOS category in the 2016 WHO classification.                
The term lipid-rich SCT has also been dropped 
from the updated nomenclature for SCT’s.                   
Lipid-rich cells with signetring- like morphology 
have been identified in variable proportions in SCT 
NOS, with/without sclerotic stroma.                                                               
Large cell calcifying SCT persists in the 2016 WHO 
classification.                                                                      
Intratubular large-cell hyalinizing Sertoli cell 
neoplasia is being added as a separate entity within 
the SCT category.
TNM Staging 
Cancer staging is a vital component of a pathological 
report and has serious implications on patient 
management. The primary purpose of TNM system 
WHO Classification
The latest fourth edition of WHO classification of 
the urinary system and male genital organs, referred 
as blue book was published after more than a decade 
in 2016 and incorporated certain significant changes 
in classification of testicular tumours. Both the 
CAP and ICCR documents incorporate the World 
Health Organization (WHO) 2016 Classification of 
Testicular Tumours.
           
 l In 2016 WHO classification, Germ Cell   
  Tumours (GCTs) are broadly categorized 
  on the basis of their association with Germ 
  Cell Neoplasia in Situ (GCNIS)
                                                                                                          
	 	 	  Those related to NIS; associated 
    with isochromosome 12p(i12p) 
	 	 	  Those not related to GCNIS; not 
    associated with i12p, found in 
    children and usually have a benign 
    or indolent behavior
ASSOCIATED to GCNIS
	 l Pure seminoma
	 l Non-seminomatous (NSGCT) tumours 
              Embryonal carcinoma
              Yolk sac tumour (YST) of    
   postpubertal type
            Teratoma of postpubertal type (including 
   teratoma with somatic type malignancy),
	 l Trophoblastic tumours 
                    Choriocarcinoma,
                    Mixed NSGCTs and regressed GCTs. 
NOT ASSOCIATED WITH GCNIS
	 l Spermatocytic tumour ,
	 l Teratomas of prepubertal type  
	 l  Yolk Sac Tumor of prepubertal type
Notable changes include                                                                     
A-Germ Cell Neoplasia in Situ which replaced the 
A Short Review of Recent Changes in WHO 
Classification and TNM Staging for Testicular 
Neoplasms in the American Joint Committee on 
Cancer in Eighth Edition of Cancer Staging Manual 
Dr Ummiya Tahir and Dr Sidra Arshad
Histopathology 
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is to provide an anatomic-based classification to 
adequately depict cancer prognosis and treatment.  
The following is the New TNM staging according to 















Primary tumor cannot be assessed
No evidence of primary tumor
Germ cell neoplasia in situ
Tumor limited to testis (including rete testis invasion) without lymphovascular invasion
Tumor smaller than 3 cm in size (applies only to pure seminoma)
Tumor 3 cm or larger in size  (applies only to pure seminoma)
Tumor limited to testis (including rete testis invasion) with lymphovascular invasion
                                                       OR
Tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer
covering the external surface of tunica albuginea with or without lymphovascular invasion
Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion
Tumor invades scrotum with or without lymphovascular invasion
Regional lymph nodes cannot be assessed
No regional lymph node metastasis
Metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five 
nodes positive, none larger than 2 cm in greatest dimension
Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension, or 
more than five nodes positive none larger than 5 cm, or evidence of extranodal extension of tumor.
Metastasis with a lymph node mass larger than 5 cm in greatest dimension
PRIMARY TUMOR (pT)




Distant metastasis – now includes discontinuous involvement of the spermatic cord by tumor in vascular spaces that have 
invaded in to spermatic cord soft tissue
Non retroperitoneal nodal or pulmonary metastases
Non pulmonary visceral metastases
DISTANT METASTASIS(pM)
	 l Text in red highlights changes introduced in the 
  recent AJCC manual, eighth edition
Reference: WHO classification of tumours of the urinary system and 
male genital organs; fourth edition
PRACTICE POINTS
GNCIS is now the preferred term for precursor 
lesions of GCTs. The absence of GNCIS in 
parenchyma adjacent to an apparent GCT, 
should prompt consideration of a diagnosis 
such as a spermatocytic tumour or a SCST.                                               
Other 2016 WHO changes include the 
distinction between prepubertal and postpubertal 
teratoma, the replacement of spermatocytic 
seminoma with the term spermatocytic 
tumour and the consolidation of previously 
recognized variants of SCT within SCT, NOS.                                 
pTNM AJCC 8th edition staging changes require 
more attention to thorough sampling of the testicular 
hilum, epididymis and spermatic cord.
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Discussion
Synovial chondromatosis is a benign monoarticular 
disorder of unknown origin which is characterized 
by metaplasia and proliferation of synovium into 
multiple intra-articular cartilaginous loose bodies 
which may calcify and ossify. 
A 26-year-old male presented to 
an outside hospital orthopedic 
OPD with a nine months history of 
insidious onset pain, stiffness and 
swelling around left knee. His knee 
pain was progressively worsening, 
aggravating by weight bearing 
activity and restricting his day to 
day activities. The swelling around 
knee was progressively increasing 
in size. There was no history of 
trauma, constitutional symptoms or 
other joint involvement. An x-ray AP 
and Lateral view was taken which 
showed soft tissue swelling with 
extensive small nodular/punctate 
calcification posteriorly. However 
underlying bone appears intact but 
exhibit mild degenerative changes.
Patient underwent limited 
synovectomy along with removal of 
multiple variable size and shape friable white loose 
bodies. Histological examination showed variable 
size and shape lobules of cartilage along with the 
synovial tissue. The chondrocytes in these lobules 
showed clustering. The combined radiological 
and histological findings were consistent with the 
diagnosis of primary synovial chondromatosis (SC). 
Radiology-Pathology Correlation; Orthopedic 
Pathology
Dr Nasir Ud Din & Dr Dawar Khan
Histopathology and Radiology
A B
Figure 1A & B. x-ray knee AP and lateral views
Figure. A & B. Low and high power examination of synovial chondromatosis. Lobules of chondrocytes are seen.
A B
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most often multiple and of uniform size.
Histologically, both primary and secondary SC 
is composed of nodules of hyaline cartilage. 
Calcification and ossification is seen in long 
standing nodules. In primary SC, the chondrocytes 
are organized in clusters within an abundant 
chondroid matrix and may show moderate 
cytological atypia and binucleation. Secondary SC 
is often associated with degenerative changes of 
the articular cartilage and bone. Cellularity is lower 
than in primary SC.
Histologically, extra-articular SC may be 
misdiagnosed as chondroma of soft parts, which 
also primarily affects the hands and feet. Chondroma 
of soft part, however typically presents as a 
solitary mass in younger patients. Primary synovial 
chondrosarcoma is extremely rare, and distinguished 
from primary SC by significant atypia, mitosis and 
underlying bone invasion.
Treatment and Prognosis
Treatment of synovial chondromatosis usually consists 
of removal of the intra-articular bodies with or without 
synovectomy, but local recurrence is not uncommon, 
occurring in ~12.5 percent (range 3-23 percent) 
of cases. Recurrences are treated by re-excision. 
Malignant transformation into chondrosarcoma has 
been reported but is extremely rare.
chronic and critical illness, infections like HIV and 
tobacco exposure.
There are various laboratory tests available to 
diagnose pancreatic insufficiency, called Pancreatic 
Function Tests including fecal fat testing, fecal 
elastase and pancreatic function test. The pancreatic 
function test is considered the most sensitive test 
for diagnosing EPI. It is an invasive procedure, 
involving a tube insertion into small intestine to 
collect pancreatic secretions and Cholecystikinin 
and secretin are measured in it. This test however is 
It is classified under two main types:
primary synovial chondromatosis: predominantly 
monoarticular disorder of unknown etiology
secondary synovial chondromatosis: resulting 
in intra-articular loose bodies from causes such 
as trauma, osteoarthritis, rheumatoid arthritis and 
neuropathic arthropathy.
The knee followed by the hip are the most commonly 
involved sites. Extra-articular SC is most prevalent 
in the tendon sheaths of the hand and feet. The age 
range is wide but most patients present in the fourth or 
fifth decades of life. Men are affected more frequently 
(M:F ratio of 2:1 to 4:1). Secondary SC usually 
arises in older patients. Patients usually present with 
pain, swelling, and limitation of motion, which often 
progresses slowly for several years. Joint effusions 
are common as there is a restricted range of motion. 
Radiological features of synovial chondromatosis 
depend on the degree of ossification that has occurred. 
When calcification is absent (one third of cases) plain 
radiographs may be normal or reveal a non-specific 
findings, e.g. soft-tissue mass surrounding the joint, 
widening of the joint space, erosions of adjacent 
bones, or early osteoarthritic changes.
When extensive ossification is present, then many 
calcific joint bodies are present, either fully ossified, 
or partly showing the ring and arc like calcifications 
characteristic of chondroid calcifications. They are 
Exocrine pancreatic insufficiency (EPI) is a 
condition caused by reduced or inappropriate 
secretion of pancreatic enzymes. EPI can result in 
clinical and biochemical manifestations causing 
reduced quality of life and in severe cases, even 
life-threating complications. The pancreatic causes 
of EPI includes, Cystic Fibrosis (the most common 
cause), acute pancreatitis, tumours involving 
the pancreas, resective pancreatic surgery and 
Schwachman-Diamond Syndrome. While extra-
pancreatic causes include, Diabetes Mellitus, 
Inflammatory bowel disease, gastric surgery, aging, 
Fecal Elastase: A Marker For Exocrine 
Pancreatic Function
Dr Faryal Husnain and Ms Saba Ijaz
Clinical Chemistry
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Figure 1: Interpretation of Fecal Elastase-1 test:
amylase, and trypsin. It has five isoforms (CELA1, 
CELA2A, CELA2B, CELA3A, and CELA3B) of 
these proteins, the biological specificity of which 
is largely unknown. The available commercial 
assay is an ELISA quantifying CELA2 and/or 
CELA3 isoforms of the human “chymotrypsin-like 
elastase”.
Elastase-1 is highly stable in feces for up to one 
week at room temperature, and for one month 
when stored at 4°C, thus making conservation 
simpler. The only caution is that the measurement 
must be performed on solid stools; liquid stool 
indeed can be associated with false-positive result. 
Interpretation of fecal elastase-1 test is shown in 
figure 1. The sensitivity of FE-1 for mild, moderate, 
and severe EPI patients is 63 percent, 100 percent, 
and 100 percent, respectively and the specificity 
for EPI is 93 percent (5) hence it is a useful tool for 
diagnosing EPI.
cumbersome, invasive, time-consuming, costly and 
also cannot detect response to pancreatic enzyme 
replacement therapy. The fecal fat testing measures 
the total fat in stool sample collected over a three 
day period. This test is also inconvenient for most 
of the aptienst because of three day stool collection 
and has low specificity to diagnose EPI. That is why 
fecal elastase is considered the test of choice. At 
the Aga Khan Clinical Laboratory we have recently 
started fecal elastase testing.
Pancreatic fecal elastase-1:
Fecal Elastase 1 is a proteolytic enzyme produced 
by pancreatic acinar cells, which binds to bile 
salts and passes through the gut with slight 
degradation, the concentration of this enzyme 
in the feces is five times higher than that in the 
pancreatic juice. Therefore, it reflects the level 
of pancreatic output and correlates also with the 
output of other pancreatic enzymes such as lipase, 
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five days and one week survival rates is 35-45 
percent. Some studies also reports survival up to 
14.5 Days (Carter et.al). Approximately five to 
ten-percent of children with Edward’s syndrome 
survive beyond their first year of life, requiring 
treatments that are appropriate for the various 
and chronic effects that are associated with the 
syndrome. Mosaic Trisomy 18 is reported in 
some cases and found associated with normal 
intelligence and long term survival (Beratis 
et.al, Collins et.al). Edward’s syndrome may be 
detected prior to the birth of the child. Potential 
testing includes maternal serum alpha-fetal 
protein analysis or screening, amniocentesis, 
ultrasonography, and chorionic villus sampling.
Molecular Cytogenetic Studies
Molecular Studies performed on a total of 10 patient 
with Partial MT 18, suggest that the region proximal 
to band 18q12 does not contribute to the Syndrome, 
whereas Two clinical response, one proximal (18 
q12.1---q 22) and one distal (18 q 22.3----qter) 
could work in co-operation to provide the typical 
trisomy 18 Phenotype (Kline et.al and Mewar et.al).
In addition, severe mental retardation in these patient 
could be associated with trisomy of the reason 18q 
12.3-------q21.1.
It is very rare syndrome and a protocol for reporting 
this critical condition is followed. In case of 
positive findings patient’s physician is informed and 
consulted for patient’s condition.
Introduction
Edward’s Syndrome is also known as Trisomy 18 
(47, XX or XY,+18) is a genetic disorder caused 
by the presence of all or part of an extra 18th 
chromosome. Trisomy 18 was first described by John 
H. Edwards in 1960. The Incidence is one in 6000 
to 8000 live births. It is more common in females, 
with a male-to-females ratio of 1:3-4. The risk of 
trisomy also increase with maternal age.  Individuals 
with trisomy 18 often have slow growth before birth 
(intrauterine growth retardation) and a low birth 
weight.
Due to the presence of several life-threatening 
medical problems, many individuals with trisomy 18 
die before birth or within their first month. Trisomy 
18 is the second most common autosomal trisomy 
after Down Syndrome Trisomy 21. Cytogenetic 
Studies of Human oocytes and sperm reveals that 
more than 90 percent of the abnormalities observed 
in oocytes and less than 50 percent of these see in 
sperm are numerical. The most common features of 
trisomy 18 includes mental and growth deficiencies, 
craniofacial dysmorphism, prominent occiput 
,narrow bifrontal, small mouth, narrow place, low-set 
malformed ears, microganthia, clenced hands with 
a tendency for the second fingers or THIRD fingers 
or polydactyl, rocker bottom feet, shortage sternum, 
cardiac anomalies ( VSD,ASD and PDA).
Life Expectancy
Currently studies showed that medico survival 
average of trisomy 18 is approximately two to 
Edward Syndrome: Rare Autosomal Aneuploidy
Ms Anum Fatima 
Molecular Pathology 
Clenched Hand Trisomy 18Rocker-Bottom feet Chromosome 18
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Patients taking sirolimus frequently require 
screening lipid profile as hypercholesterolemia 
has been observed in patients taking sirolimus 
during first six months after transplant. At Aga 
Khan Clinical laboratory Sirolimus is recently 
introduced. Whole blood sample is required for the 
Sirolimus test. 
Sirolimus is a substrates for cytochrome 
P450 3A, the co-administration of sirolimus 
with cytochrome P450 3A inducers (some 
anticonvulsants, rifampin, isoniazid, St. John’s 
wort) and with cytochrome P450 3A inhibitors 
(such as azole antifungals, non-dihydropyridine 
calcium channel blockers, some macrolide 
antibiotics, grapefruit) can result in significant 
interactions. Toxicity of this drug can lead 
to leukopenia, thrombocytopenia, anemia, 
hypercholesterolemia, hypertriglyceridemia, 
proteinuria, diarrhea, constipation and dyspepsia. 
Regular monitoring of sirolimus blood levels is 
recommended to avoid these side effects.
Sirolimus, a hydrophobic macrolide compound 
is derived from antinomycete, Streptomyces 
hygroscopicus. It is a potent immunosuppressant 
(suppression of T- and B-cell proliferation) 
selectively blocking the transcriptional activation 
of cytokines thus inhibiting cytokine production. It 
becomes active when bound to immunophilins. It 
also acts as an antimicrobial, antifungal agent.
Sirolimus is used to prevent cellular rejection after 
organ transplantation, especially renal transplant, heart 
allografts and stem cell transplant recipients. It has been 
approved for use in combination with cyclosporine 
and also it can be used as a substitute of calcineurin 
inhibitor. It is advised to use sirolimus in conjunction 
with cyclosporine and corticosteroid as it reduces the 
incidence of acute rejection in renal transplant patients 
without producing overall adverse effects.
Following entry into the cytoplasm, sirolimus binds to 
the FK binding protein and presumably modulate the 
activity of the mTOR. The mTOR inhibits interleukin 
(IL)-2-mediated signal transduction, resulting 
in cell-cycle arrest in the G1-S phase. Sirolimus 
block the response of T and B cell activation by 
cytokines, which prevents cell-cycle progression 
and proliferation. Sirolimus available in two form; 
liquid solution and tablet both primarily partition in 
red blood cells and is metabolized through hepatic 
and intestinal microsomal system (CYP3A4). The 
pharmacokinetics is defined in Table 1.
Sirolimus in Renal Transplant
Dr Bilal Hashmi and Ms Maria Masood 
Clinical Chemistry









Oral solution (14%), tablets (27% higher)
12 L/kg, with 97 percent of the agent 




degree. Patient centered health care is now the talk 
of the town. This consists of small handheld devices 
and desktop equipment that can be used for testing 
outside of patient care facilitates, some even in the 
Medical laboratory science technology has 
progressed over the course of last few decades at 
a very rapid rate and the lab gurus have projected 
the progression to continue developing at a similar 
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with wearable sensor based devices have greatly 
assisted this cause, as they can monitor and record 
real-time data on from the individuals body and then 
with connectivity to central lab via smart phones can 
log and archive it in the central health records. Such 
devices are now being worked into smart bands, 
attire, and can even be fastened in the forms of light 
belts to the body. For current and future medical 
laboratory scientists it is necessary to explore 
broader horizons in this context and lining up with 
smart technology is inevitable for the advancement 
of clinical laboratories.
D) Rapid Specimen Transportation
As specimen transport has seen various 
developments in the past few years from conveyer 
belts to pneumatic tubes, the use of drone to 
transport specimens from distant locations to a 
central laboratory as practiced successfully by the 
Swiss post in Switzerland has tremendously changed 
the game for the laboratories worldwide.  Drones 
not only add to major cost costing, reduces laborious 
task, saves time for the end uses, reduces turnaround 
time for the laboratories and helps them expand their 
outreach to distant locations. 
E) Bio-banks
Bio banks serves as bio repository that stores 
human biological samples for its utility in various 
clinical aspects like transfusion, transplantation and 
research & development. Since the early 90s they 
have become an important resource for clinical 
laboratories, serving as a major contributor for 
present-day research like genomics, biomarker 
discovery and individualized medicine. The network 
of bio banks in Europe and North America is widely 
established and major work is required to be done 
from our part of the world to shape in line with the 
needs of the time.
Developments in technology will continue to impact 
laboratory services; and how we translate them into 
practice alongside training & education of future 
laboratorians with the ultimate aim of providing a 
better patient focused health care.
comfort of home by the patient himself via home 
based health monitoring systems whose data can be 
transmitted with a click through smart gadgets to 
centers where it is processed; rather than the patient 
himself being present at the testing facility leading 
to further reduction in expenses. Its high need of 
time to enhance our current understanding on these 
advancements, especially the following five areas:
A) Point-of-care Testing
Point of care testing (POCT) is medical testing that 
is performed outside of a laboratory setting. POCT 
testing commonly referred to as bedside testing or 
near-patient testing. It enables medical staff to make 
rapid triage and treatment decisions when diagnosing 
a patient’s condition or monitoring a treatment 
response. With the current advances in POCT testing, 
alongside the provision of expanding menu of tests, 
devices can transmit results wirelessly and in real-
time to the patients’ electronic medical record. Some 
systems have been updated with features designed 
to assess real time quality control and achieving 
regulatory compliance.
B) Automation
Since the advent of the continuous flow analyzer 
in the 1950s, laboratory automation has continued 
to evolve and expand its capabilities to become 
inevitable for the survival of any clinical 
laboratory. From a broader perspective, a laboratory 
automation system consists of robots, conveyor 
systems, machine vision, and computer hardware 
and software. Modern automated systems have 
significantly improved the throughput from pre-
analytical right to the post-analytical phase.
C) Self-Monitoring with Wearable Sensors
With an alarming increase globally in the number 
of elderly population with numerous health issues, 
home based self-monitoring is on the rise keeping 
in mind the comfort and ease of care alongside 
major cost cutting, as opposed to costly health care 
facilities that are at times may be considerably 
distant. The current era of modern smart technology 
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Ollier’s disease and PHACE syndrome have been 
documented.
The most common sites of origin are the cerebellum 
and around third ventricle; however, the entire 
neuraxis can be afflicted
Pilomyxoid astrocytoma a variant is characterized 
by uniform bipolar cells in a myxoid background and 
frequent perivascular arrangements
Anaplastic Transformation (Pilocytic Astrocytoma 
With Anaplasia):
In a subsequent series, anaplasia in pilocytic 
astrocytoma was found to occur primarily in the 
form of diffuse, brisk mitotic activity (usually > 4 




strongly express GFAP 
and S100. 
The Ki-67 proliferation 
index is low in most cases.
Genetic Profile
Most of the Pilocytic 
astrocytomas harbour 
a transforming fusion 
A 20 years old female presented 
in the emergency with history of 
headache, vomiting and a few 
episodes of loss of consciousness. 
On detailed investigations, MRI 
was performed which showed a 
large cystic lesion in right cerebellar 
hemisphere with enhancing solid 
mural nodule.  
          
Patient underwent craniotomy and 
biopsy was sent. Histopathology 
examination showed a biphasic 
pattern with variable proportions 
of compacted bipolar cells with 
Rosenthal fibers and loose, textured 
multipolar cells with micro cysts 
and occasional granular bodies.  No 
cytological atypia or significant mitosis were seen. 
Final diagnosis of Pilocytic astrocytoma was made 
after radiological –pathological correlation.
Discussion
Pilocytic astrocytoma (PA) accounts for 5.4 
percent of all gliomas and is the most common 
glioma in children and adolescents, with no gender 
predilection.
According to WHO classification of CNS tumors 
(2016) they are classified as WHO grade I tumors, 
and have a relatively good prognosis.
PA is usually sporadic, however, associations 
with, Turcot syndrome, neurofibromatosis type 1, 
Radiology-Neuropathology Correlation
Dr Tamanna Asghari, Dr Sidra Arshad and Dr Shayan Sirat 
Histopathology and Radiology 
A B
MRI - TIW post contrast axial image (A) and sagittal T2W midline 
image (B): A large cystic lesion in right cerebellar hemisphere with 
enhancing solid mural nodule.
Fig A&B show Bipolar cells with Rosenthal fibres, granular bodies and microscystic spaces.
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Pilomyxoid astrocytoma (PMA) is a rare variant 
of PA. It frequently occurs in the suprasellar/ 
chiasmatic/hypothalamic region. They are aggressive 
grade II tumors and are mainly solid, exhibiting 
homogenous or heterogeneous rim enhancement. 
PMAs display higher degree of internal haemorrhage, 
leptomeningeal spread and expected local recurrence. 
No significant differentiating imaging features 
have been described in literature for Pilocytic 
astrocytoma with anaplasia, however it is thought 
to be more solid than cystic. Hence, only histology 
can predict the true nature of this disease.
Prognostic and Predictive Factors
 l Overall survival rates at five and ten years 
  are > 95 percent after surgical intervention 
  alone 
 l Pilocytic astrocytomas of the optic nerve 
  in patients with NF1 seem to have a more 
  indolent behaviour than that of their sporadic 
  counterparts. 
 l Patient age and extent of resection are key 
  prognostic factors
Treatment
 l The treatment of choice for PA is gross total 
  resection and is generally curative. 
 l In case of residual disease, control of tumor 
  progression can be achieved by re-excision 
  and stereotactic radiosurgery.  
 l Pilocytic astrocytoma with anaplastic 
  features warrant radiation therapy and/or 
  chemotherapy.
An association has been reported between the 
increased measurement of NT and fetal anomalies, 
aneuploidies, genetic disorders, and abortions. 
NT scan in the late first trimester in conjunction 
with maternal age and serum biomarkers has been 
established as an effective method for trisomy 
screening . The accuracy of NT scan for detection of 
Down syndrome is from 29 percent to 100 percent, 
with the false positive rate being 0.3 percent to 11.6 
Nuchal Translucency Scan 
NT (Nuchal translucency) is the sonographic 
finding in the first trimester due to the subcutaneous 
fluid collection behind the fetal neck. The cause 
for increased NT thickness includes structural 
malformation leading to cardiac failure, disorders 
of extracellular matrix and developmental delay or 
abnormality of the lymphatic.
Nuchal Translucency Scan 
Dr Shaista Afzal
Radiology
gene between KIAA1549 and BRAF gene. This 
constitutively activates the MAPK pathway.
Imaging
‘A cystic mass with an enhancing mural nodule’ 
is the typical manifestation of majority of PAs on 
imaging. The pertinent differentials of posterior fossa 
pilocytic astrocytoma include: medulloblastoma, 
ependymoma, hemangioblastoma, atypical teratoid/
rhabdoid tumor(ATRT) and abscess. The first 
two entities are midline tumors and mostly solid; 
hemangioblastoma is tumor of adults and occurs 
in children when associated with von hipple lindau 
disease; ATRT are aggressive looking large solid 
masses and abscess have typical clinical presentation.
 
Fifty percent of the tumors are cystic, with a mural 
nodule. Solid component enhances invariably (~95 
percent) and the cyst wall enhances in 50 percent of the 
cases. Non-necrotic solid tumors are uncommon and 
account for only 10 percent of cases. Up to 20 percent 
may demonstrate some calcification. Hemorrhage is an 
infrequent complication. There is signal loss on T2*/
SWI in case of calcification/hemorrhage.
On diffusion-weighted imaging, the cystic component 
of the mass displays the diffusion characteristics of 
CSF. The low cellularity of PA is supported by high 
apparent diffusion coefficient (ADC) values within the 
solid component of the tumor. 
Magnetic resonance spectroscopy (MRS) to 
evaluate CPA have demonstrated high choline, low 
N-acetylaspartate (NAA) and high lactate levels. These 
features are usually identified with high grade tumours.
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percent. Early diagnosis can guide through early 
management and proper counseling strategy which 
can be implemented to lessen the mental trauma of 
the expectant parents.
It is important to take gestational age i.e.  11 to 13+6 
and crown rump length (CRL) range from 45 to 84 
mm into account as NT value is between 50TH and 
95th percentile with these values and it increases 
with growth of these parameters . The mid sagittal 
plane of fetus should be achieved for NT evaluation. 
An important factor that affects NT measurement 
is the fetal neck position. The measurement can be 
decreased by 0.4 mm with fetal neck flexion and 
increased by 0.6 mm with extension of fetal neck 
flexion.  Hence as a standard, for NT measurement 
the fetal head should be in a neutral position. The 
fetal position in relation to the amniotic membrane 
can be a source of error, therefore nuchal edge should 
be seen separate from the amniotic membrane .The 
correct positioning of calipers i.e. in an “on and on” 
position and adequate image magnification with fetus 
occupying at least ¾ of the screen size is important 
to reduce variability in measurements. At least three 
measurements and the mean value of NT should 
be obtained for evaluation of risk assessment and 
counseling of patients in case of abnormal results.
The competency of the staff enhances the accuracy 
and reproducibility of the scan and requires 
appropriate training approved by certifying agencies.
Also, for accuracy of measurement there should 
be provision of good quality ultrasound machines 
with option of multiple frequencies transducers and 
availability of transvaginal scanning, especially with 
obese patients.
Conclusion
NT evaluation is important in the first trimester as its 
increased measurement is associated with a spectrum 
of fetal chromosomal and structural abnormalities. 
Accurate and reproducible NT measurement requires 
strict follow-up of the quality guidelines for the 
training, supervision, and technique of the sonologist. 
Ultrasound scan in first trimester, CRL of 63 mm corresponding to 12 
weeks and five days. 
NT measure 1.3mm
implemented to prevent unintentional exposure to 
biological agent or toxins and also to prevent their 
accidental release. While laboratory biosecurity 
explain the protection, control and accountability for 
any biological agent or toxins within laboratory in 
order to prevent their misuse, loss or unauthorized 
access or intentional unauthorized access.  
Bio-risk Management System 
The identification of bio-risks Bio-risk management 
system includes: biohazard identification, 
assessment, management and communication
All laboratories are responsible for biosafety and 
biosecurity and it is necessary to protect their 
workers, population and environment from exposure 
or spread any harmful pathogen. This important 
function is accomplished by two major actions: 
1. No handling of any specified bio-risk in their 
 facility.
2. By identifying, implementing and maintaining 
 biosafety and biosecurity measures. 
Laboratory biosafety describes the containment 
principles and technologies that are need to be 
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Biohazard identification, which is identification of 
the biological agent, amount and concentration; 
bio-risk assessment, which includes the possible 
biological risk, susceptible species and health 
consequences of an exposure or release from the 
facility, available laboratory resources and severity 
of harm, potential for theft or misuse; bio-risk 
management is a process that requires documentation 
of timelines for action, assignment of responsible 
persons and completion of reporting; while bio-risk 
communication is the interactive and exchange of 
information and opinions throughout the risk analysis 
process about risk analysis, risk related factors 
among the risk communicators or general public/
patients. 
The laboratory manager work with bio-risk 
management committee to identify which risk 
control measure is appropriate and feasible for use in 
their laboratory. The bio-risk system consist of four 
elements, administrative, operational, engineering 
control and personal protective equipment.
Administrative control includes laboratory safety/
security policies, management programs, qualified 
trained and competent personnel, training in safe 
and secure handling of biological agents and toxins, 
health and safety programs, incident and accident 
investigation programs, Emergency response and 
contingency plans, biological agent and toxin 
inventory management plans, waste management 
policies and security policies (i.e. facility security, 
visitor or personnel access).
Operational control includes standard operating 
procedures for all biosafety and biosecurity processes, 
good laboratory safety practices, disinfection and 
decontamination practices, specimen and reagent 
handling or proper storage practices, fire or other 
drills, incident reporting or response procedures.
Engineering Control includes facility ventilation, 
biological safety cabinets, physical security which 
may include access restrictions, security guards, bio-
metric devices.   
Personal protective equipment includes gloves 
(hand protection), face mask, N95 respirator, face 
shield, hood (face protection), Laboratory coat (body 
protection). 
The goal is to identify appropriate control measures 
for the laboratory, determine if suitable control 
measures currently exist in the laboratory, identify 
additional control measures that the laboratory 
can implement on fiscal resources and available 
infrastructure and implement the control measure.  It 
is an ongoing process in which specific laboratory 
bio-risk control measures are regularly monitored.
Chronic kidney disease is associated with a decrease 
in kidney function that is often progressive. Early 
detection of kidney dysfunction can help to minimize 
the damage. This is important as symptoms of 
kidney disease may not be noticeable until as much 
as 30-40 percent of kidney function is lost. Kidney 
function estimation was commonly made using 
Serum Creatinine (SCr) concentration, blood urea 
nitrogen (BUN) level and urine analysis. However 
accumulating evidence has demonstrated that these 
biomarkers are not optimal to detect kidney disease 
in early stages. Literature have reported GFR to 
Every day, healthy kidneys filter about 189 liters of 
blood and produce about 1.5-2 liters of urine. The 
GFR refers to the amount of blood that is filtered 
by the glomeruli per minute, and is a measure of 
kidney function. As a person’s kidney function 
declines due to damage or disease, the GFR 
decreases and waste products begin to accumulate 
in the blood. GFR values are associated with age, 
sex and body surface and are 120 and 130 mL/min 
per 1.73 m2 in young men and women, respectively. 
Methods of determination of estimated GFR are 
shown in Table 1.
Estimated Glomerular Filtration Rate (GFR): 
A Serum Creatinine-Based Test for the 
Detection of Chronic Kidney Disease (CKD)
Dr Siraj Muneer and Mr. Abdul Mateen
Clinical Chemistry
29
VOL. 45, ISSUE 2JULY 2019
Table1: Methods of determination and estimation of GFR and their evaluation
Table 2: Stages of Chronic Kidney Disease
Measuring GFR by clearance of exogenous substances
Inulin (gold standard), iohexol, 51Cr-EDTA, 125I-iothalamate, 99mTC-
diethylenetriaaminepentaacetic acid (DTPA)
Measuring GFR by clearance of endogenous substances
Creatinine Clearance (CrCl) = (urine Cr x urine volume)/Serum Cr
Estimated GFR (eGFR)
Creatinine based Schwartz Equation (for children)
eGFR (mL/min/1.73 m2)= 0.413 x [height (cm)/Scr (mg/dL)]
Cockcroft Gault Equation
eGFR= {([140-age] × weight in kg)/(serum creatinine × 72)} x (0.85 if female)
MDRD Equation
186 x (Cr/88.4)-1.154 x  (Age)-0.203 x  (0.742 if female) x  (1.210 if black)
CKD-EPI
GFR = 141 x min(Scr/κ,1)α x max(Scr/κ, 1)-1.209 x  0.993Age x 1.018 [if female] x 1.159 [if black]
κ is for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the 
minimum of SCr/ κ or 1 and max indicates the maximum of SCr/ κ or 1
CKD-EPI-Pak
GFR (ml/min per 1.73 m2) = 0.686 x CKD-EPI 1.059
be a better marker for assessing kidney function 
compared to SCr. In clinical practice GFR is crucial 
for diagnosis, management, 
drug dosing and prognosis, 
in addition to its utility for 
research and public health. 
The KDIGO recommends 
that CKD be diagnosed, 
classified, and staged by 
GFR, shown in Table 2.
At Aga Khan Clinical 
Laboratories, eGFR is 
reported using the SCr 
results by CKD-EPI-Pak 
formula. This formula 
was first validated on a 
previous performed SCr 
and results were compared 
with the other formulas, 
MDRD, Cockcroft Gault 
and CKD-EPI taking 
creatinine clearance as the 
gold standard (1). Estimated 
glomerular filtration rate 
is the best test to measure 
level of kidney function and 
determine the stage of kidney 
disease. The GFR provides 
information regarding 
stage of kidney disease and 
helps the doctor plan the 
treatment. The earlier kidney 
disease is detected the better 










Kidney damage with normal GFR
Kidney damage with mild ↓ GFR
Mild to moderate ↓ GFR
Moderate ↓ GFR
Severe ↓ GFR
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Urine organic acid (UOA) 
analysis is crucial for 
diagnosis of inherited 
metabolic disorders, including 
the organic acidemias 
involving propionic, 
methylmalonic, and isovaleric 
acidemias, other disorders 
such as biotinidase deficiency, 
Canavan’s disease, and 
certain amino acidopathies 
like phenylketonuria and 
Tyrosinemia as well. The UOA 
chromatograms interpretation 
is difficult, diagnosis requires a 
certain expertise for accuracy 
as misinterpretation can lead to 
a wrong diagnosis. It is essential 
that laboratorians have good understanding 
of the normal and abnormal patterns of UOA 
chromatogram to reach a diagnosis. To achieve 
this, Section of Chemical Pathology, Department 
of Pathology and Laboratory Medicine conducted 
a half day flipped workshop for consultants and 
trainees involved in management of inherited 
metabolic diseases (IMDs) patients. This workshop 
was arranged under the auspices of International 
Federation of Clinical Chemistry and Laboratory 
Medicine and Pakistan Society of Chemical 
Pathologist on Saturday, March 2nd 2018.
Picture 1: Facilitator presenting to workshop participants.
Picture 2: Workshop participants doing group activities.
The focus of workshop was on understanding of 
internal quality control (IQC), proficiency testing 
(PT), as well as hands on skills to interpret IQC 
and PT results and running root cause analysis 
(RCA) to identify root cause of errors. Workshop 
started with introduction of all participants 
followed by a pretest quiz via online Kahoot 
game to challenge participants’ thinking. This 
was followed by lectures covering the basics in 
urine organic acid testing, including a talk on 
‘An overview of urine organic acids from IMDs 
perspective’ by Dr Aysha Habib, Section Head 
Chemical Pathology. Second talk was on ‘GC-MS 
A Hands on Workshop on ‘Urine Organic 
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and Application of Chromatography in Organic 
acids Testing’ by Dr. Lena Jafri, director of the 
workshop. Last talk of the session was on ‘Correct 
Identification of Organic Acids and Metabolites 
using the libraries’ by Dr. Hafsa Majid, followed 
by an interactive group activity on chromatogram 
labelling and interpretation. In the end participants 
were given different case studies for diagnosis to 
assess their understanding of UOA chromatograms 
interpretation.
This workshop was well attended by wide range 
of enthusiastic participants including, residents, 
technologists and pathologists from different sub-
specialties of Pathology, from more than five institutes/
laboratories of Karachi. The participants found the 
workshop very insightful and comprehensive. They 
welcomed these opportunities for more in-depth 
understanding of UOA chromatograms labelling and 
peer interaction and thanked the organizers for sharing 
their rich educational experience.
Picture 3: Group Photo of Workshop organizers and participants.
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Dr Sheema Hasan: 
There were innumerable 
moments when I felt really 
satisfied. Throughout our 
carriers second opinions 
are sought on our cases. 
These may be reviewed 
by other national or 
international pathology 
centers. So early in my 
carrier there was a case on 
which the reviewed report 
had a different diagnosis 
and the patient family was very angry.  I felt very 
low at that time, but few months’ later patient had 
a recurrence at the same site and second biopsy had 
features similar to the diagnosis that I rendered on 
the first biopsy. 
As the senior most histopathologist of the 
country, please share your experience of 
development of Histopathology field in Pakistan.
Dr Sheema Hasan: In those days the 
histopathology was practiced in isolation 
as individuals and there was no concept of 
intradepartmental or inter consultation or 
clinicopathlogical sessions. We pioneered the 
practice of group discussions and interacted 
with colleagues through interdepartmental and 
departmental conferences (DCC) and with 
clinicians’ (Clinicopathological conferences 
& tumor board meetings), thus building up 
long lasting relationships and trust between the 
pathologists and clinicians. We started participating 
in international forums and started national 
presentations and workshops. We also started 
structured residency program in all specialties 
of Pathology. Now when I look around it gives 
us great pleasure to see our trainees’ working as 
established and renowned consultant within the 
country and abroad. 
Any advice for young histopathologist?
Dr Sheema Hasan: There are many shortcuts to 
failure but there are no shortcuts to true success. 
Through hard work and discipline one can 
accomplish anything. 
Considering your entire time as a 
Histopathologist at Aga Khan University, 
can you recall a time (any ‘AHA’ moment) when 
you felt most excited about your involvement in 
the organization?
Dr Sheema Hasan: A moment in 35 Years, Humm. 
Well it cannot be a moment. It was the first few 
years when I was really excited. It was the time 
when laboratory became functional and we, a small 
group of consultants and technologists took the task 
of laying the foundation of what later became a 
symbol of quality and excellence in the country. We 
all worked very hard with one goal in mind that the 
histopathology section at AKU evolves as the very 
best in the country with an international repute. 
After 35 years now I feel proud to see that we have 
done it!!  
What was your inspiration to become a 
histopathologist? Please briefly share your initial 
phase of journey i.e. from medical graduate to 
consultant.
Dr Sheema Hasan: As a medical graduate or even 
in first few years of my career, I never thought of 
choosing histopathology as my specialty. I guess the 
reason was the lack of exposure to histopathology 
or clinical laboratory, in a broader sense, during 
the days of medical school. I chose Gynecology/
Obstetrics as an intern and later did three years of 
training in medicine. After my marriage I moved 
to London, but the job opportunities to practice 
Medicine were less there. Therefore, I moved to 
Plymouth where I lived alone and started practicing 
Medicine.  It was then that I decided to choose 
some other field as I had to move back to London 
to join my family. I applied for pathology residency 
in Kingston Hospital, affiliated with Kings College 
and was selected. During residency I developed 
interest in histopathology and cytopathology. It 
was the gold standard in diagnostics, and I liked 
the work environment of histology section of the 
institute. Since then I never looked back and never 
regretted the choice that I made.
Share your one moment when you felt most 
proud as a histopathologist.
The Best of the Past 
#Pathologists #Followtheirlead #changeagents 
Interview Recorded by 
Dr Sidra Arshad
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AKU histopathology faculty participated in Joint 9th Annual conference of ‘Histopathology& Cytology Society of 
Pakistan(HCSP)’and 6th Annual conference of ‘International Academy of Pathology (IAP)-Pakistan Division  held at 
Marriott’s Islamabad from April 20-21, 2019. It is a forum that brings together histopathologists and trainee nationwide. 
The scientific program included talks from well renowned International speakers including Prof Emad  Rakha from 
University of Nottingham, UK, an authoritative figure in the field of Breast Pathology among others
Group picture of the participants and organizers of a multidisciplinary conference on ‘Newborn screening for inherited 
metabolic disorders in Pakistan’ in line with world rare day
Polaroid
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Pakistan Journal of Radiology(PJR) celebration of continuous 10 years of publishing with legendry Dr Rashid Ahmed-
Tamgha-e-Imtiaz 2017; patron-in-chief of PJR [Right] and Dr Syed Mahmood-Dean faculty of Radiology CPSP [left]
Group picture of the participants and organizers of “Coagulation and Haemostasis workshop” conducted at the annual 
conference of Pakistan Society of Haematology
Polaroid
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Meeting of Global Mycetoma working Group at NNN (Neglected tropical diseases NGO Network) in September 2018 at 
Addis Ababa, Ethiopia 
Participants: Briana Reeves and Karlyn D Beer (CDC\DDID\NCEZID), Alexendar Tiendrebeoge, Kingsley Bampoe 
Danieal Arggaw, Ashok Moloo (WHO), Afia Zafar and Mohammad Zeeshan (AKUH)
First Molecular Cytogenetic workshop conducted by AKU Molecular pathology faculty at AFIP, Rawalpindi, Pakistan
Polaroid
hospitals.aku.edu/Karachi/clinical-laboratories
